Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis

被引:0
|
作者
Li, Sheng-Li [1 ]
Xu, Peng [2 ]
Zhang, Lei [2 ]
Sun, Gui-Xiang [3 ]
Lu, Zhao-Jun [3 ]
机构
[1] Xuzhou Med Coll, Affiliated Hosp, Stat Off Informat Ctr, Xuzhou 221004, Peoples R China
[2] Xuzhou Med Coll, Affiliated Hosp, Dept Radiol, Xuzhou 221004, Peoples R China
[3] Xuzhou Med Coll, Sch Publ Hlth, Xuzhou 221004, Peoples R China
来源
HIV CLINICAL TRIALS | 2015年 / 16卷 / 01期
关键词
Rilpivirine; Non-nucleoside reverse transcriptase inhibitor; HIV-1; Efavirenz; Meta-analysis; HIV-1-INFECTED PATIENTS; VS; EFAVIRENZ; TMC278; ECHO; PHASE-3; THRIVE; EFFICACY; RECOMMENDATIONS; GUIDELINES; RESISTANCE;
D O I
10.1179/1528433614Z.0000000007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The aim of this study was to determine the effectiveness and safety of rilpivirine in treatment-naive adults infected with HIV-1. Methods: We ran duplicate searches of multiple databases and searchable websites of major HIV conferences (up to October 2013) to identify randomized controlled trials reporting the effectiveness and safety of rilpivirine in treatment-naive adults infected with HIV-1. Reference lists from retrieved articles were also reviewed. Data were extracted independently in duplicate using predefined data fields. All analyses used random-effects models to calculate the summary treatment effect estimates. Results: Four randomized controlled trials with a total of 2522 patients were included in the inclusion criteria. The primary efficacy endpoint was the proportion of patients with confirmed HIV-1 RNA levels of <50 copies/ml (viral load) at 48 weeks. Rilpivirine demonstrated non-inferior antiviral efficacy in viral load comparable with efavirenz at 48 weeks [relative risk (RR)=1.03, 95% confidence interval (CI): 0.99-1.07]. The mean changes from baseline in CD4 count were similar in both rilpivirine and efavirenz (RR=1.05, 95% CI: 0.85-1.24). Rilpivirine showed higher and significant difference in virological failure rates comparing with the efavirenz group (RR=1.70, 95% CI: 1.21-2.38). The incidences of the most commonly reported adverse events related to study medication, including rash, and neurological events, were lower with rilpivirine than with efavirenz (RR=0.11, 95% CI: 0.03-0.33; RR=0.52, 95% CI: 0.45-0.60, respectively). Conclusions: Current evidence suggests a range of favorable effects and a generally favorable safety profile of rilpivirine in treatment-naive adults infected with HIV-1 at week 48.
引用
收藏
页码:22 / 29
页数:8
相关论文
共 50 条
  • [1] Effectiveness and Safety of Rilpivirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive Adults Infected with HIV-1: A Meta-analysis
    Li, Sheng-li
    Xu, Peng
    Zhang, Lei
    Sun, Gui-xiang
    Lu, Zhao-jun
    [J]. HIV CLINICAL TRIALS, 2014, 15 (06): : 261 - 268
  • [2] Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection
    Ripamonti, Diego
    Maggiolo, Franco
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (08) : 899 - 912
  • [3] HIV-1 non-nucleoside reverse transcriptase inhibitor
    Lloyd, AW
    [J]. DRUG DISCOVERY TODAY, 1998, 3 (08) : 387 - 387
  • [4] CHARACTERIZATION OF THE BIOTRANSFORMATION OF THE HIV NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR RILPIVIRINE
    Lade, Julie M.
    Bumpus, Namandje N.
    [J]. DRUG METABOLISM REVIEWS, 2014, 45 : 186 - 187
  • [5] Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review
    Schafer, Jason J.
    Short, William R.
    [J]. ANTIVIRAL THERAPY, 2012, 17 (08) : 1495 - 1502
  • [6] Etravirine: A unique non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1
    Girotto, Jennifer E.
    [J]. FORMULARY, 2010, 45 (03) : 78 - +
  • [7] TREATMENT PATTERNS AND DRUG TREATMENT COSTS ASSOCIATED WITH NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)-BASED ANTIRETROVIRAL THERAPY IN TREATMENT-NAIVE HIV-1 INFECTED PATIENTS
    Diels, J.
    Langham, S.
    Nuyts, G.
    Adriaenssen, I
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A116 - A117
  • [8] Antiviral activity, safety and pharmacokinetics IDX899, a novel HIV-1 non-nucleoside reverse transcriptase inhibitor with high barrier to resistance, in treatment-naive HIV-1-infected patients
    Murphy, R.
    Zala, C.
    Zhou, X. J.
    Pictropaolo, K.
    Sullivan-Bolyai, J.
    Belanger, B.
    Mayers, D.
    [J]. ANTIVIRAL THERAPY, 2008, 13 (04) : A27 - A27
  • [9] Structure and dynamics of the non-nucleoside inhibitor TMC278/rilpivirine bound to HIV-1 reverse transcriptase
    Kuroda, Daniel G.
    Challa, J. Reddy
    Troxler, Thomas
    Bauman, Joseph D.
    Patel, Disha
    Arnold, Eddy
    Hochstrasser, Robin M.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [10] Etravirine - A non-nucleoside reverse transcriptase inhibitor for the treatment of resistant HIV-1 infection
    Kehr, Heather A.
    Olin, Jacqueline L.
    Love, Bryan L.
    [J]. FORMULARY, 2008, 43 (03) : 105 - +